REPLIGEN CORP. overview

Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety...

Thinking about trading options or stock in Repligen, Zendesk, United Airlines, Dollar Tree, or BioNTech? PR Newswire NEW YORK, March 15, 2022 NEW YORK , March 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RGEN, ZEN, UAL, DLTR, and BNTX. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of...

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (Nasdaq: RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current...

EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen PR Newswire NEW YORK, Dec. 8, 2020 NEW YORK , Dec. 8, 2020 /PRNewswire/ -- EC Mergers & Acquisitions ("EC M&A") is pleased to confirm the sale of ARTeSYN BioSolutions ("ARTeSYN") ARTeSYN is a manufacturer of innovative single-use solutions for the downstream bioprocessing industry. The Company is growing rapidly, led by the success of its single-use chromatography and filtration systems which are considered the gold standards in...

NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Repligen Corporation (NASDAQ: RGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018, at 8:30 AM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/22638 . To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor...

NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Repligen Corporation (NASDAQ: RGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 8:30 AM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/22638 . To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor Network...